Clinical Trial Details
| Trial ID: | L2139 |
| Source ID: | NCT01697631 |
| Associated Drug: | Biphasic Insulin Aspart 30 |
| Title: | Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: biphasic insulin aspart 30|DRUG: insulin aspart |
| Outcome Measures: | Primary: HbA1c (glycosylated haemoglobin) | Secondary: 7-point blood glucose profile|Correlation of endpoint HbA1c with baseline BMI (body mass index) and HbA1c with treatment mode stratification|Incidence of adverse events|Hypoglycaemic episodes (minor, major or nocturnal) |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 131 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2002-07-22 |
| Completion Date: | 2003-04-24 |
| Results First Posted: | |
| Last Update Posted: | 2017-02-24 |
| Locations: | Novo Nordisk Investigational Site, Bialystok, 15-276, Poland|Novo Nordisk Investigational Site, Bytom, 41-902, Poland|Novo Nordisk Investigational Site, Kamieniec Zabkowicki, 57-230, Poland|Novo Nordisk Investigational Site, Katowice, 40-053, Poland|Novo Nordisk Investigational Site, Krakow, 31-261, Poland|Novo Nordisk Investigational Site, Nysa, 48-300, Poland|Novo Nordisk Investigational Site, Otwock, 05-400, Poland|Novo Nordisk Investigational Site, Radom, 26-600, Poland|Novo Nordisk Investigational Site, Ruda Slaska, 41-700, Poland|Novo Nordisk Investigational Site, Sosnowiec, 41-200, Poland|Novo Nordisk Investigational Site, Warsaw, 01-877, Poland|Novo Nordisk Investigational Site, Wroclaw, 50-306, Poland |
| URL: | https://clinicaltrials.gov/show/NCT01697631 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|